trial

The Effects of tDCS on Illness Awareness in Schizophrenia

NCTId NCT02848885
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 32 (actual)
Sponsored by Centre for Addiction and Mental Health
Primary completion 2025-05-13
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
32 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2016-08
Primary completion
2025-05-13
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Active TDCS

Sponsors

Centre for Addiction and Mental HealthLead Sponsor

Investigators

1
Philip Gerretsen, MD, PhDPrincipal Investigator

Sites

1 total
Toronto, Canada

Facts & assertions

4 sourced
Enrollment
32
Phase
NA
Primary Completion Date
2025-05-13
Status
COMPLETED
relationships
The graph out of here
drug
Active TDCS
drug
lead_sponsor
Centre for Addiction and Mental Health
company
indication
Schizophrenia
indication
Schizophrenia
indication
Agnosia
indication
investigator
Philip Gerretsen, MD, PhD
person